GSK2830371|cas 1404456-53-6|DC Chemicals

GSK2830371|cas 1404456-53-6|DC Chemicals

GSK2830371 is an orally active, allosteric Wip1 phosphatase inhibitor with IC50 of 6 nM.

Product Name: GSK2830371 |Catalog Number: DC8422 |CAS 1404456-53-6 |Other names: GSK2830371,GSK 2830371,GSK-2830371 |Chemical Name: (S)-5-((5-chloro-2-methylpyridin-3-ylamino)methyl)-N-(3-cyclopentyl-1-(cyclopropylamino)-1-oxopropan-2-yl)thiophene-2-carboxamide |Molecule Formular: C23H29ClN4O2S |MW: 461.02

In the PPM1D-amplified MCF7 breast carcinoma cells, GSK2830371 increases the phosphorylation of multiple Wip1 substrates, including p53 (S15), Chk2 (T68), H2AX (S139) and ATM (S1981). GSK2830371 shows selective antiproliferative activity in a subset of lymphoid cell lines, all of which carry a wild-type TP53 allele. Furthermore, co-treatment of doxorubicin and GSK2830371 results in a synergistic antiproliferative effect in DOHH2 and MX-1 tumor cells. [1]In vivo, GSK2830371 increases phosphorylation of Chk2 (T68) and p53 (S15) and decreases Wip1 protein concentrations in DOHH2 tumors. GSK2830371 (150 mg/kg p.o.) also inhibits the growth of DOHH2 tumor xenografts via inhibition of Wip1. [1] For the detailed information of GSK2830371, the solubility of GSK2830371 in water, the solubility of GSK2830371 in DMSO, the solubility of GSK2830371 in PBS buffer, the animal experiment (test) of  GSK2830371, the cell expriment (test) of GSK2830371, the in vivo, in vitro and clinical trial test of GSK2830371, the EC50, IC50,and affinity,of GSK2830371, For the detailed information of GSK2830371, the solubility of GSK2830371 in water, the solubility of GSK2830371 in DMSO, the solubility of GSK2830371 in PBS buffer, the animal experiment (test) of  GSK2830371, the cell expriment (test) of GSK2830371, the in vivo, in vitro and clinical trial test of GSK2830371, the EC50, IC50,and affinity,of GSK2830371, Please contact DC Chemicals.

For research and scientific purpose only, not for human use.